Abstract

Diabetes in India is reaching epidemic proportions. Prevalence of diabetes have heightened because of rapid cultural changes such as increased urbanization, modified diet patterns and sedentary lifestyles among the young generation. In 2013, 30 million people were in the Prediabetes group whereas 61.5 million people suffered from diabetes in India. The medication for the diabetic population such as OHA and Insulins is the need of the hour since the disease is adding significantly to the mortality rate of India. The Indian insulin market has seen a growth of 13.9 CAGR between financial year 2008 and 2013. Indian insulin market is witnessing tremendous development and is yet to mature. With a huge base of diabetic patients, it is estimated that only 25 of this population is receiving the treatment. Unawareness about diabetes backed by low affordability has left the major proportion of the diabetic populace to remain untreated. However, In India the disposable income is increasing which is leading to better accessibility of healthcare services and enhanced diagnostics which will further broaden the patient base, create opportunities for insulin companies operating in the coming years. Human insulin is being solely used in comparison to the analog insulin in the Indian diabetic population due to the fact that it's cheaper. The revenue from human insulin registered a CAGR of 10.5 during Financial year 2008 2013. Although the share of human insulin has been more since financial year 2008, but the market captured by analog insulin has been growing rapidly with a CAGR of 20.4 during financial year 2008 2013. Seeing the growth of Indian diabetic market, it has become a very lucrative market for insulin multinationals. Companies including Novo Nordisk, Eli Lilly and Sanofi dominate the landscape and had a share of more than 85 in the Indian insulin market in financial year 2013. With a superior product portfolios and marketing strategies such as alliances, the 3 companies have gained a monopoly over the market. Domestic enterprises including Biocon, Lupin and Wockhardt therefore face stiff competition from the foreign counterparts. Prabhsimran Singh | Prof. (Dr.) Harvinder Popli "Competitive Landscape of Insulin Market in India" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-4 , June 2019, URL: https://www.ijtsrd.com/papers/ijtsrd24018.pdf Paper URL: https://www.ijtsrd.com/pharmacy/other/24018/competitive-landscape-of-insulin-market-in-india/prabhsimran-singh

Authors and Affiliations